Pretreatment tumor standardized uptake value as a prognostic factor in primary head and neck squamous cell carcinoma

Zhang,Baitao; Nie,Fang; Jin,Bin; Meng,Qinghong; Dong,Pin

doi:10.3892/mco.2014.464

Pretreatment tumor standardized uptake value as a prognostic factor in primary head and neck squamous cell carcinoma

Authors:
- Baitao Zhang
- Fang Nie
- Bin Jin
- Qinghong Meng
- Pin Dong
View Affiliations

Affiliations: Department of Otolaryngology-Head and Neck Surgery, Shanghai First People's Hospital, Shanghai Jiao Tong University, Shanghai 200080, P.R. China, Department of Intensive Care Medicine, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai 200001, P.R. China
Published online on: November 21, 2014 https://doi.org/10.3892/mco.2014.464
Pages: 392-396

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Our objective was to conduct a systematic review and meta‑analysis of studies assessing the diagnostic performance of primary tumor standardized uptake value (SUV) in head and neck squamous cell carcinoma (HNSCC), as measured by positron emission tomography. A systematic search of the indexed medical literature was conducted using appropriate keywords to identify relevant studies. Six articles were identified by searching electronic databases. a statistical analysis was performed with RevMan 4.2.2 software. SUV measurement and the SUV threshold for defining high SUV were studied dependently. For each publication, we first obtained an estimate of the relative risk (RR) for comparing patients with a low and those with a high SUV. Subsequently, we aggregated the individual RRs into a combined RR using the fixed‑effects model to yield weighted mean pooled estimates with 95% confidence intervals (CIs). Publication bias was assessed with a funnel plot. A total of 6 clinical trials involving 453 patients were included in the meta‑analysis. The combined RR from the 6 reports for local control was 0.72 (95% CI: 0.63‑0.81). The funnel plot revealed symmetrical distribution, indicating no evidence of significant publication bias. The increase in the SUV of the primary tumor was found to be a poor prognostic marker for patients with HNSCC in the meta‑analysis, which requires further confirmation in a meta‑analysis based on individual patient data.

View Figures

View References

1	Lydiatt WM, Shah JP and Hoffman HTHead Neck Sites Task Force. American Joint Committee on Cancer: AJCC stage groupings for head and neck cancer: should we look at alternatives? A report of the Head and Neck Sites Task Force. Head Neck. 23:607–612. 2001. View Article : Google Scholar : PubMed/NCBI
2	Osman I, Sherman E, Singh B, et al: Alteration of p 53 pathway in squamous cell carcinoma of the head and neck: impact on treatment outcome in patients treated with larynx preservation intent. J Clin Oncol. 20:2980–2987. 2002. View Article : Google Scholar : PubMed/NCBI
3	Izzo JG, Papadimitrakopoulou VA, Liu DD, et al: Cyclin D1 genotype, response to biochemoprevention and progression rate to upper aerodigestive tract cancer. J Natl Cancer Inst. 95:198–205. 2003. View Article : Google Scholar : PubMed/NCBI
4	Ang KK, Berkey BA, Tu X, et al: Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma. Cancer Res. 62:7350–7356. 2002.PubMed/NCBI
5	Rohren EM, Turkington TG and Coleman RE: Clinical applications of PET in oncology. Radiology. 231:305–332. 2004. View Article : Google Scholar : PubMed/NCBI
6	Minn H, Clavo AC, Grenman R and Wahl RL: In vitro comparison of cell proliferation kinetics and uptake of tritiated fluorodeoxyglucose and L-methionine in squamous-cell carcinoma of the head and neck. J Nucl Med. 36:252–258. 1995.PubMed/NCBI
7	Haberkorn U, Strauss LG, Reisser C, et al: Glucose uptake, perfusion, and cell proliferation in head and neck tumors: relation of positron emission tomography to flow cytometry. J Nucl Med. 32:1548–1555. 1991.PubMed/NCBI
8	Vansteenkiste JF, Stroobants SG, Dupont PJ, De Leyn PR, Verbeken EK, Deneffe GJ, Mortelmans LA and Demedts MG: Prognostic importance of the standardized uptake value on18F-fluoro-2-deoxy-glucose-positron emission tomography scan in non-small-cell lung cancer: an analysis of 125 cases. Leuven Lung Cancer Group. J Clin Oncol. 17:3201–3206. 1999.PubMed/NCBI
9	Berghmans T, Dusart M, Paesmans M, et al European Lung Cancer Working Party for the IASLC Lung Cancer Staging Project: Primary tumor standardized uptake value (SUVmax) measured on fluorodeoxyglucose positron emission tomography (FDG-PET) is of prognostic value for survival in non-small cell lung cancer (NSCLC): a systematic review and meta-analysis (MA) by the European Lung Cancer Working Party for the I ASLC Lung Cancer Staging Project. J Thorac Oncol. 3:6–12. 2008. View Article : Google Scholar : PubMed/NCBI
10	Brun E, Kjellen E, Tennvall J, et al: FDG PET studies during treatment: prediction of therapy outcome in head and neck squamous cell carcinoma. Head Neck. 24:127–135. 2002. View Article : Google Scholar : PubMed/NCBI
11	Allal AS, Slosman DO, Kebdani T, Allaoua M, Lehmann W and Dulguerov P: Prediction of outcome in head-and-neck cancer patients using the standardized uptake value of 2-[18F]fluoro-2-deoxy-D-glucose. Int J Radiat Oncol Biol Phys. 59:1295–1300. 2004. View Article : Google Scholar : PubMed/NCBI
12	Kim SY, Roh JL, Kim MR, et al: Use of18F-FDG PET for primary treatment strategy in patients with squamous cell carcinoma of the oropharynx. J Nucl Med. 48:752–757. 2007. View Article : Google Scholar : PubMed/NCBI
13	Roh JL, Pae KH, Choi SH, et al: 2-[18F]-Fluoro-2-deoxy-D-glucose positron emission tomography as guidance for primary treatment in patients with advanced-stage resectable squamous cell carcinoma of the larynx and hypopharynx. Eur J Surg Oncol. 33:790–795. 2007. View Article : Google Scholar : PubMed/NCBI
14	Liao CT, Chang JT, Wang HM, et al: Pretreatment primary tumor SUVmax measured by FDG-PET and pathologic tumor depth predict for poor outcomes in patients with oral cavity squamous cell carcinoma and pathologically positive lymph nodes. Int J Radiat Oncol Biol Phys. 73:764–771. 2009. View Article : Google Scholar : PubMed/NCBI
15	Torizuka T, Tanizaki Y, Kanno T, Futatsubashi M, Naitou K, Ueda Y and Ouchi Y: Prognostic value of18F-FDG PET in patients with head and neck squamous cell cancer. AJR Am J Roentgenol. 192:W156–W160. 2009. View Article : Google Scholar : PubMed/NCBI
16	Allal AS, Dulguerov P, Allaoua M, Haenggeli CA, EI-Ghazi el A, Lehmann W and Slosman DO: Standardized uptake value of 2-[18F] fluoro-2-deoxy-D-glucose in predicting outcome in head and neck carcinomas treated by radiotherapy with or without chemotherapy. J Clin Oncol. 20:1398–1404. 2002. View Article : Google Scholar : PubMed/NCBI
17	Burk D, Woods M and Hunter J: On the significance of glucolysis for cancer growth, with special reference to Morris rat hepatomas. J Natl Cancer Inst. 38:839–863. 1967.PubMed/NCBI